

Remarks

Claims 10-21 and 101-103 are pending in this application. Claims 104-105 are canceled without prejudice to Applicants' right to pursue the subject matter recited by them in one or more divisional, continuation, or continuation-in-part applications. No new matter has been introduced.

Applicants appreciate the Examiner's recognition that claims 10-21 are allowable. Applicants respectfully submit that other pending claims are also allowable for the following reasons.

A. The Rejection Under 35 U.S.C. § 112, ¶1 Should Be Withdrawn

On pages 2-3 of the Office Action, claims 104-105 are rejected as allegedly failing to comply with the written description requirement for the reasons stated therein. Although Applicants respectfully disagree with the Examiner's contentions, claims 104-105 are canceled, without prejudice to Applicants' right to pursue the subject matter recited by them in related applications. In view of the cancellation of these claims, Applicants respectfully request that the rejection under 35 U.S.C. § 112 be withdrawn.

B. The Objection to Claims 101-103 Are Obviated

On page 3 of the Office Action, claims 101-103 are objected to as allegedly confusing. The Examiner recommends that structural delineation be made of record. To accommodate the Examiner's recommendation, claims 101-103 are amended to recite the chemical structures of individual species encompassed by claim 10 or 14.


Please note that the compound N-{{2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisindolin-4-yl}methyl}undecamide (**I-78**), which is not encompassed by the genus recited by claim 10, but was inadvertently included in claim 101, is excluded from that claim. Furthermore, the compounds N-{{2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisindolin-4-yl}methyl}(cyclohexylamino)carboxamide (**I-85**) and cyclopropyl-N-{{2-(3-methyl-2,6-dioxo(3-piperidyl))-1,3-dioxoisindolin-4-yl}methyl}carboxamide (**I-139**), both of which are encompassed by the genus recited by claim 10, but were inadvertently excluded from claim 102, are added to that claim.

In view of these amendments, Applicants respectfully request that the objection to claims 101-103 be withdrawn.

No fee is believed to be due for this submission. However, should any fees be required for the submission of this paper, or to avoid abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Respectfully Submitted,

Date: May 6, 2005


Max Bachrach 45,479
Reg. No.
Jones Day
51 Louisiana Avenue, N.W.
Washington, DC 20001
(202) 879-3939

Anthony M. Insogna (Reg. No. 35,203)
Jones Day
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1200